Tianyuan Zhou News Today : Breaking News, Live Updates & Top Stories | Vimarsana

 E-Mail
Many patients with multiple myeloma, a type of blood cancer, eventually develop resistance to one treatment after another. That s in part because cancer stem cells drive the disease cells that continually self-renew. If a therapy can t completely destroy these malignant stem cells, the cancer is likely to keep coming back.
Researchers at University of California San Diego School of Medicine and Ionis Pharmaceuticals are taking a new, targeted approach to myeloma treatment silencing IRF4, a gene that allows myeloma stem cells and tumor cells to proliferate and survive. Past studies have shown that high IRF4 levels are associated with lower overall survival rates for patients with the disease. ....

San Diego , United States , University Of California San Diego , Ashnia Vora , Caitlin Costello , A Robert Macleod , Tianyuan Zhou , Catriona Jamieson , Elisa Lazzari , Phoebek Mondala , Xiaolin Luo , Youngsoo Kim , Translational Research Institute , National Cancer Institute , Drug Administration , Division Of Regenerative Medicine , Oncology At Ionis Pharmaceuticals , Sanford Stem Cell Clinical Center , Cancer Research , Uc San Diego Health , Ionis Pharmaceuticals , Moores Cancer Center , Uc San Diego School Of Medicine , California San Diego School , Cell Stem , Leslie Crews ,